Scroll Up
Scroll Down
Play Play Play Play
Unregistered User
Click here if this is not your Personal Edition
 
Contact Us | Free E-Mail Updates | Journals | Register a colleague
 
 
Pain
 
   
 
SEARCH   
Doctor's Guide Free CME
Medline
Congress Resource Centre
 

 EXPLORE :
   Most Read News
 All News  All News
 All Webcasts / CME  All Webcasts / CME
 All Cases  All Cases
 Congress Resource Centre  Congress Resource Centre
 All Medical Resources  All Medical Resources
 Medical  My Personal Edition



Warning | Privacy

 

 
 Recent news - Pain
    TopAbstracts in Pain 11/27/2008 - (DGNews)
    FDA Approves Tapentadol for Relief of Moderate to Severe Acute Pain - (DGNews)
    TopAbstracts in Pain 11/20/2008 - (DGNews)
    TopAbstracts in Pain 11/13/2008 - (DGNews)
    TopAbstracts in Pain 11/06/2008 - (DGNews)

    News archive

     Recent webcasts/CME - Pain
      Chronic Pain Patients on Opioid Therapy
      Chronic Pain Management in Primary Care: Individualizing Pain Relief and Improving Quality of Life
      Acute Pain Management and Opioid Treatment: Community Pharmacist Perspectives
      Enhanced NSAID Delivery: Emerging Technologies
      Balanced Opioid Prescribing

      Webcasts/CME archive

       Recent cases - Pain
        Pain in Both Knees
        Ketamine as an Adjuvant in Sympathetic Blocks for Management of Central Sensitization Following Peripheral Nerve Injury
        Sciatica Due to Extrapelvic Heterotopic Ossification: A Case Report
        Factitious Lymphoedema as a Psychiatric Condition Mimicking Reflex Sympathetic Dystrophy: A Case Report
        Gluteal Pyomyositis as a Rare Cause of Sciatica in a Temperate Region: A Case Report

        Cases archive
          




        my personal edition > pain > news
        divider

          E-Mail this DGReview to a colleague

        DGReview


        Anti-Epileptic Drug Levetiracetam May Relieve Pain With Minimal Side Effects

        A DGReview of :"Levetiracetam in the treatment of neuropathic pain: three case studies"
        Clinical Journal of Pain

        12/30/2003
        By Emma Hitt, PhD


        Levetiracetam, a new antiepileptic drug, appears to be effective in treating neuropathic pain, according to an analysis of 3 case studies.

        The pharmacologic therapy for neuropathic pain using traditional pain treatments or analgesic drugs is often unsuccessful. Levetiracetam (Keppra, UCB Pharma, Inc.) has a favourable side-effect profile and does not interact with other drugs. Similarities in the pathophysiology and biochemistry of neuropathic pain and epilepsy, has led to the use of this drug class in these conditions.

        In his report, Michael J. Price, MD, with the Wuesthoff Memorial Hospital, Rockledge, Florida, United States, describes the outcome of 3 patients treated in his office.

        One patient, a 55-year-old woman, presented with numbness and pain in both lower extremities. The pain was of sudden onset and of 4 months' duration, and was determined to be peripheral neuropathy with mild axonal and demyelinating features.

        Initial treatment with oral thiamine and topiramate provided minimal benefits and caused unacceptable adverse effects. The woman was switched to 1500 mg twice a day of levetiracetam plus nortriptyline, and this resulted in a 60% improvement in pain symptoms.

        The second case was a 75-year-old man, who presented with numbness in both feet beginning 5 years earlier. The numbness had progressed to persistent pain, resulting in sleep disruption. Oral thiamine did not relieve the pain; however, 500 mg levetiracetam once in the evening completely resolved his pain and improved his sleep.

        The third case involved a 67-year-old obese male with progressive dysfunction in both lower extremities that developed over a 1-year period. Walking caused pain that disrupted sleep at night. Treatment with 1000 mg levetiracetam twice a day completely resolved the pain.

        According to Dr. Price, levetiracetam appears to be an effective therapy in the treatment of neuropathic pain, causing a low incidence of adverse events and improving patients' sleep.

        "Over time these benefits appear to have been sustained," the author notes, and "controlled clinical trials would be warranted to support the findings obtained in these studies," he adds.
        Clin J Pain. 2004;20:33-36. "Levetiracetam in the treatment of neuropathic pain: three case studies"

        E-Mail this DGReview to a colleague   To print, use this version






        All contents Copyright (c) 1995-2008 Doctor's Guide Publishing Limited. All rights reserved.



        The NTK initiative. Physicians helping physicians identify Need-To-Know science
           Feedback
        Please rate this article: Strongly DISAGREE...Strongly AGREE NTK logo
        Question 1 - Physicians need to become aware of this information as soon as possible. Question 2 - This information is likely to have an impact on the way physicians practice medicine.
        1
        2
        3
        4
        5
        6
        7
        Send